IPILIMUMAB IN COMBINATION WITH NVOLUMAB

- **Cohort 2:** 12 patients; receiving 0.3 mg/kg of ipilimumab q6w and nivolumab 3 mg/kg q2w until disease progression or discontinuation due to toxicity or a maximum of 12 weeks (2 cycles).

- **Cohort 1:** AGEN1884 1 mg/kg q6w / AGEN2034 1 mg/kg q2w

**Results**

- Both nivolumab and ipilimumab were administered intravenously in clinic at the study sites to ensure correct administration and to review for any adverse reaction.

- A gating strategy was utilized to identify CD4+ T cells, CD8+ T cells, and regulatory T cells, CD56+ NK cells, CD56++ NK cells, and NKT cells.

- 12 patients were enrolled to receive ipilimumab 0.3 mg/kg q6w / nivolumab 3 mg/kg q2w.

- 9 patients were enrolled to receive ipilimumab 1.0 mg/kg q6w / nivolumab 3 mg/kg q2w.

**CONCLUSIONS**

- There was a trend of increased Ki-67 expression with higher doses of AGEN1884 and AGEN2034 in combination treatment of patients with advanced solid tumors.

**References**


